GLP1R and type 2 diabetes mellitus: In adults with new onset type 2 diabetes, GLP‐1 receptor agonist and SGLT‐2 inhibitor utilization has markedly increased, coordinating with evolving guidelines that emphasize cardiovascular and chronic kidney disease management.